SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001136261-22-000332
Filing Date
2022-11-10
Accepted
2022-11-10 16:06:48
Documents
62
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 body10-q.htm   iXBRL 10-Q 1307263
7 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER exh31-1.htm EX-31.1 10431
8 CERTIFICATION OF CHIEF FINANCIAL OFFICER exh31-2.htm EX-31.2 10420
9 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS exh32-1.htm EX-32.1 3343
10 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS exh32-2.htm EX-32.2 3356
  Complete submission text file 0001136261-22-000332.txt   5551896

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE seel-20220930.xsd EX-101.SCH 37975
3 XBRL CALCULATION FILE seel-20220930_cal.xml EX-101.CAL 36021
4 XBRL DEFINITION FILE seel-20220930_def.xml EX-101.DEF 197100
5 XBRL LABEL FILE seel-20220930_lab.xml EX-101.LAB 303452
6 XBRL PRESENTATION FILE seel-20220930_pre.xml EX-101.PRE 281201
56 EXTRACTED XBRL INSTANCE DOCUMENT body10-q_htm.xml XML 818297
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

IRS No.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22245 | Film No.: 221377088
SIC: 2834 Pharmaceutical Preparations